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ABSTRACT Stimulation of erythropoiesis during growth
is necessary to ensure proportionality between erythrocyte
mass and body mass. However, the way by which erythrocyte
formation is adapted to body growth is still unknown. Growth
arrest in hypophysectomized rats is accompanied by decreased
erythropoiesis. We have, therefore, examined whether insulin-
like growth factor I (IGF-I), the mediator of growth hormone
effects-on body growth, is able to restore erythropoiesis in these
animals. Subcutaneous infusions of 120 ,ug of recombinant
human IGF-I per day in hypophysectomized rats led to
increases in body weight, "9Fe incorporation into erythrocytes,
and the number of reticulocytes that were similar to increases
caused by infusions of 28 mifliunits of human growth hormone
per day. Body weight gain and 59Fe incorporation were linearly
correlated. Like growth hormone, IGF-I also caused a signif-
icant rise in serum erythropoietin concentrations. However,
the stimulatory effect on erythropoiesis occurred before serum
erythropoietin levels had risen. These results demonstrate that
IGF-I mediates the stimulatory effect of growth hormone on
erythropoiesis in vivo and thus further support the somatome-
din concept. They also show that IGF-I can stimulate erythro-
poiesis in an endocrine manner, and they sggest two possible
routes of action: a direct one and an indirect one by means of
enhanced erythropoietin production.
It is well established that erythrocyte (RBC) mass increases
in strict proportion to the body mass during the growth period
of mammals (1). This proportionality is physiologically im-
portant because it ensures that increased oxygen consump-
tion during growth is matched by an increased oxygen
transport capacity. However, the way by which this adap-
tation is brought about is unknown. Since erythropoiesis in
the adult is primarily controlled by erythropoietin (Epo) (2),
one could assume that Epo is ofmajor importance also within
this adaptive process. Epo is mainly produced by the kid-
neys. Its production rate is thought to be related to the ratio
of renal oxygen demand to renal oxygen supply (2). One
might therefore speculate that the increase of kidney mass
during growth causes an increased renal oxygen consumption
and, in consequence, a relative renal deficiency ofoxygen. In
turn, an enhanced rate of Epo production would lead to
stimulation of erythropoiesis and thus adapt RBC mass to
body growth. However, ,he recent observation that massive
hypertransfusion of mice and rats during rapid growth does
not fully suppress erythropoiesis (3, 4) argues against this
concept. Therefore, the question arises whether factoks other
than Epo may contribute to the stimulation of erythropoiesis
during growth. Obvious candidates for such a function are
growth hormone (GH) and insulin-like growth factor I (IGF-
I).
Growth arrest in hypophysectomized rats is not only
accompanied by low IGF-I serum levels (5, 6) but also by
reduction of erythropoiesis (7, 8). GH has been reported to
Stimulate erythropoiesis in hypophysectomized rats in vivo
(9-11) and in vitro (12, 13). IGF-I, a polypeptide hormone of
molecular mass 7649 and a structural homologue of insulin
(14), might well be a common denominator for the regulation
of whole body mass and RBC mass: its synthesis is governed
by GH (15), there is unambiguous evidence that it mediates
GH effects (6, 16, 17), and it enhances erythropoiesis in vitro
(18-20). Therefore, we investigated the effect of IGF-I on
erythropoiesis in vivo and compared it with that of GH. To
this end, hypophysectomized rats were infused with human
GH or recombinant human IGF-I (rhIGF-I) through subcu-
taneously implanted miniosmotic pumps, and body weight,
e incorporation into RBCs, the number of reticulocytes,
and serum erythropoietin levels were determined.
MATERIALS AND METHODS
Animals. Normal male Tif RAI rats and male Tif RAI rats
6-8 weeks after hypophysectomy were used. The rats were
5 weeks old at the time of hypophysectomy. Hypophysec-
tomy was kindly performed by R. Cortesi (Ciba-Geigy,
Basel). The animals had free access to food and water and
were matched with respect to body weight in the various
experimental groups. Body weight ranged from 120 to 140 g
and was recorded daily during the experiments.
Experiments with GH and IGF-I. Hypophysectomized rats
were implanted subcutaneously with miniosmotic pumps
(Alzet, model 2001) and infused for 6 days with saline
(control), human GH [28 milliunits (mu)/day; Nanormon,
Nordisk], or rhIGF-I [120 ,ug/day; gift from W. Rutter
(Emeryville, CA) and J. Nuesch (Ciba-Geigy, Basel)]. On the
second or fourth day of the infusion five rats per group were
injected intraperitoneally with 2 ,.Ci (1 Ci = 37 GBq) of 59Fe
per 100 g ofbody weight. Forty-eight hours after the injection
the rats were anesthesized in ether and bled by heart
puncture. Blood of each rat was collected in heparin-coated
and nonheparinized plastic tubes. The latter was kept on ice
for 1 hr and centrifuged for 15 min at 1500 x g and 40C. Serum
was stored at - 20TC. The fractional 59Fe incorporation into
RBCs was determined in heparinized blood and calculated
according to the following generally used formula: % 59Fe
incorporation = (radioactivity per ml of blood/total radio-
activity injected) x blood volume (ml) x 100. Simultaneous
determinations of blood volume (51Cr method) and 59Fe
Abbreviations: IGF-I, insulin-like growth factor I; RBC, erythro-
cyte; Epo, erythropoietin; GH, growth hormone; rhIGF-I, recom-
binant human IGF-I: mu, milliunit(s).
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FIG. 1. 59Fe incorporation into RBCs of hypophysectomized rats infused subcutaneously with saline, human GH (28 mu/day), or rhIGF-I
(120 gg/day). Control, nonhypophysectomized. Data are means ± SEM of five animals per group. Rats were injected with 2 uCi of 59Fe per
100 g of body weight on days 2 and 4 of the infusion and 59Fe incorporation into RBCs was determined in whole blood 48 hr later.
incorporation in the same animal were not possible because
of overlap of the 51Cr and 59Fe spectra. Therefore, blood
volume was calculated according to published data (21) as
6.6% and 5.8% of the body weight for normal and hypophy-
sectomized rats, respectively. Aliquots of heparinized blood
were also taken for determination ofhematocrit, erythrocyte,
and reticulocyte counts.
Experiments with Epo. To quantitate the effect of Epo on
59Fe incorporation in hypophysectomized rats, the following
experiments were performed. A pool of rat serum containing
high levels ofEpo was prepared by exposing normal male rats
to normobaric hypoxia (8% 02) for 18 hr. Epo activity of the
pool was 1.3 u/ml, as determined with the exhypoxic polycy-
themic mouse assay for Epo (22). Hypophysectomized rats
(five animals per group) were injected subcutaneously every
12 hr for 4 days with 1 ml of different dilutions of the
Epo-enriched pool corresponding to 125, 250, 500, and 1000
mu of Epo per injection. Fifty-four hours after the first Epo
injection the animals received intraperitoneally 2 ,Ci of 59Fe
per 100 g of body weight. Forty-eight hours later-i.e., 6 hr
after the last Epo injection-they were bled by heart punc-
ture. Blood was collected as described above.
Determination of Epo and IGF-I. Serum concentrations of
Epo were determined by radioimmunoassay (RIA) as de-
scribed in detail (23). Epo-enriched rat serum was used as a
standard that had been calibrated in the exhypoxic polycy-
themic mouse assay for Epo (22). Each sample was measured
in duplicate in three separate assays.
Serum IGF-I was determined at the end of the infusion
experiments by RIA (24) using rabbit antiserum (final dilu-
tion, 1:20,000) batch 6656/251074 (gift from the late K. Reber,
Hoffmann-La Roche, Basel) against human IGF-I. Pure rat
IGF-I was not available during the study to perform standard
curves for the determination of endogenous rat IGF-I. The
latter was, therefore, expressed in human ng equivalents.
Recently, we were able to use pure rat IGF-I (kindly supplied
by M. Kobayashi, Fujisawa Pharmaceutical, Osaka, Japan)
as a standard and found that endogenous rat IGF-I levels are
4- to 6-fold higher than the corresponding human ng equiv-
alents.
After acidification of the sera, IGF-I was separated from
IGF carrier proteins on Sep-Pak C18 cartridges (Waters
Associates). The extraction protocol supplied with the so-
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FIG. 2. Correlation between body weight gain and 59Fe incorpo-
ration into RBCs of individual hypophysectomized rats infused
subcutaneously with saline, human GH, or rhIGF-I. If a linear
regression curve is calculated one obtains 59Fe incorporation = 29.5
+ 6.7x (body weight gain); r = 0.72.
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Table 1. Number and percentage of reticulocytes in the blood of hypophysectomized rats infused
with saline, human GH, or rhIGF-I
Reticulocyte count
After 4 days After 6 days
Cell number x 10-6 Cell number x 10-6
Infusion per.ul of blood % RBCs per ul of blood % RBCs
Saline 0.22 ± 0.02 4.3 ± 0.3 0.23 ± 0.02 4.5 ± 0.4
Human GH 0.33 + 0.03* 6.8 ± 0.6* 0.32 ± 0.01* 5.7 ± 0.3*
rhIGF-I 0.30 ± 0.02* 5.6 ± 0.4* 0.39 ± 0.04* 7.7 ± 0.6*
Data are presented as means ± SEM (n = 5). Human GH, 28 mu/day; rhIGF-I, 120 ,ug/day.
*P < 0.05 vs. saline, Student's t test.
matomedin C RIA kit from Immuno Nuclear (Stillwater, MN)
was followed. Recovery of added human IGF-I was between
92% and 103%. After reconstitution with 1 ml of phosphate-
buffered saline (pH 7.4) containing 0.2% serum albumin, all
samples were assayed at three different dilutions.
Statistics. Levels of significance were calculated by using
Student's t test.
RESULTS
In saline-infused hypophysectomized rats serum levels of
immunoreactive IGF-I were 6 + 3 human ng equivalents/ml
(mean + SEM; n = 10), as compared to 200-250 human ng
equivalents/ml in normal (nonhypophysectomized) rats. In-
fusion of 28 mu of human GH per day over 6 days in
hypophysectomized rats induced an increase of the endoge-
nous IGF-I serum level to 40 + 8 human ng equivalents/ml
(mean + SEM; n = 6) corresponding to 160-240 ng/ml (see
Materials and Methods). By the sixth day ofthe infusion with
rhIGF-I, IGF-I serum levels had risen to 208 + 32 ng/ml
(mean + SEM; n = 10). These increases in serum IGF-I
levels were accompanied by a nearly linear increase in body
weight between the second and sixth day of infusion: mean
body weight gain per day was 2.23 + 0.17 g for GH and 2.58
+ 0.46 g for rhIGF-I (mean SEM; n = 10). Hypophysec-
tomized control animals infused with saline or injected with
Epo-enriched rat serum did not gain weight.
The effects of GH and IGF-I on erythropoiesis were
assessed by measurement of the hematocrit, the number and
percentage of reticulocytes, and 59Fe incorporation into
newly formed RBCs on the second, fourth, or sixth day ofthe
infusion as indicated in the corresponding figures and tables.
The hematocrit in hypophysectomized control animals was
0.30 + 0.02 (mean + SEM; n = 10), as compared to 0.35 +
0.03 in normal rats (mean + SEM; n = 15),and did not
change during GH or rhIGF-I infusion.
59Fe incorporation into newly formed RBCs under the
infusion ofGH or IGF-I is shown in Fig. 1. It was significantly
decreased (46%) in hypophysectomized rats. Both GH and
IGF-I stimulated 59Fe incorporation to near normal already
after 2 days of infusion and had restored it completely on day
4. When 59Fe incorporation into RBCs of the individual
animals is plotted against body weight gain a positive corre-
lation between the two indices is obtained (Fig. 2).
As shown in Table 1, GH and IGF-I caused a significant
increase of the number and percentage of reticulocytes,
another index of erythropoiesis, after 4 and 6 days of
infusion.
Since Epo is considered as the major determinant of
erythropoiesis in vivo (2), we tried to find out whether or not
the stimulatory effects of GH or rhIGF-I on erythropoiesis
are mediated by Epo. Serum Epo levels were, therefore,
measured by RIA (23) after different times of infusion of
saline, GH or rhIGF-I (Table 2). No change of the serum Epo
levels was observed after 2 days ofinfusion ofGH or rhIGF-I.
After 4 days, GH and IGF-I had caused a 50o increase of the
serum Epo concentration, which rose to >150% over that of
saline-treated controls after 6 days of GH or rhIGF-I treat-
ment.
To determine whether the rise of serum Epo was sufficient
to account for the stimulation of erythropoiesis during the
infusion of GH and IGF-I, we examined the effect of
exogenous rat Epo on serum Epo levels and on 59Fe incor-
poration into RBCs of hypophysectomized rats. Serum Epo
concentrations were raised by repeated subcutaneous injec-
tions of Epo-enriched rat serum (Fig. 3). This treatment led
to a dose-dependent increase of 59Fe incorporation into
RBCs (Fig. 3). During Epo as well as during GH or rhIGF-I
treatment 59Fe incorporation and serum Epo concentrations
were linearly correlated (Fig. 4). However, the correlation
coefficients are different for the Epo and the GH or IGF-I
treatment. Interestingly, 59Fe incorporation and serum Epo
of normal (nonhypophysectomized) rats fit well into the
correlation obtained for GH or rhIGF-I-treated hypophysec-
tomized rats.
DISCUSSION
This study was designed to examine whether subcutaneous
infusions of GH and rhIGF-I, the mediator ofGH effects on
body growth, are capable of stimulating decreased erythro-
poiesis in hypophysectomized rats. We found that resump-
tion of growth by GH and IGF-I treatment was accompanied
by a significant enhancement of erythropoiesis as monitored
by increased 59Fe incorporation into RBCs and by an in-
crease in the number and percentage of reticulocytes but no
change of the hematocrit. It is important to note that body
weight gain parallels the increase in tibial epiphyseal width
and organ weights during GH and IGF-I treatment of hy-
pophysectomized rats (6). From the above findings one may
infer that both hormones increased RBC formation and thus
RBC mass to an extent sufficient to refill the expanding
intravascular volume during growth. This conclusion is
supported by the positive correlation between 59Fe incorpo-
ration into RBCs and body weight gain of the individual
animals (Fig. 2). Thus, the stimulation of erythropoiesis by
GH or IGF-I parallels the increase in body weight.
Our results obtained with GH are consistent with reports
in the literature that repeated subcutaneous injections ofGH
Table 2. Effects of subcutaneous infusions of saline, human GH,
and rhIGF-I on serum concentrations of immunoreactive Epo in
hypophysectomized rats
Serum Epo concentration, mu/ml
Infusion 2 days 4 days 6 days
Saline 24.1 ± 3.5 22.4 ± 2.4 20.0 ± 2.2
Human GH 28.8 ± 4.1 35.3 ± 10.6 53.5 5.9*
rhIGF-I 25.9 ± 2.0 32.4 ± 4.7t 51.8 + 7.6*
Data are presented as means ± SEM (n = 5).
*P < 0.005 vs. saline.
tP < 0.025 vs. saline.
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FIG. 3. 59Fe incorporation into RBCs of hypophysectomized rats
receiving repeated subcutaneous injections of Epo-enriched rat
serum. 59Fe incorporation is plotted as a function of the dose of Epo
administered per injection. Data are means + SEM of five animals
per group. Serum Epo levels measured 6 hr after the last injection
were 19 ± 11 (no Epo injection) and 23 ± 1.7, 26 ± 2.2, 28 ± 2.8,
and 30 ± 3.0 mu/ml (mean ± SEM) for the four administered Epo
doses.
in hypophysectomized animals stimulate erythropoiesis in
proportion to the increase in body weight and blood volume
without affecting the erythrocyte concentration in the blood
(10, 11, 21) and lead to a time-dependent increase in serum
Epo levels (12). Beyond that, however, this study shows that
(i) IGF-I itself in the absence ofGH stimulates erythropoiesis
in vivo, (it) IGF-I is able to exert this effect in an endocrine
fashion, and (iii) IGF-I mediates the effect of GH on eryth-
ropoiesis and Epo synthesis, which further supports the
somatomedin concept (25). The latter conclusion is based on
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the following reasoning: infusion of 28 mu of GH per day or
120 pug of rhIGF-I per day raised the plasma levels of
endogenous immunoreactive rat IGF-I from 6 ± 3 human ng
equivalents/ml (corresponding to 24-36 ng/ml) to 40 + 8
human ng equivalents/ml (corresponding to 160-240 ng/ml)
and that of circulating exogenous human IGF-I to 208 ± 32
ng/ml, respectively. Thus, the endogenous (rat) and exoge-
nous (human) IGF-I levels during GH or rhIGF-I infusion are
comparable. They are also comparable with respect to their
biological potencies, because partially purified rat IGF-I,
standardized in our RIA against human IGF-I, was found to
be three to five times more active than human IGF-I on DNA
synthesis of rat calvaria cells in vitro (26). The similar rise of
IGF-I, whether induced endogenously by means of GH
administration or effected by infusion of exogenous human
IGF-I, is accompanied by increases in 59Fe incorporation,
reticulocyte number, and serum Epo levels that are similar
for both treatments (Fig. 1, Tables 1 and 2).
A provocative question results from our study: Is the
stimulation of erythropoiesis by GH or IGF-I due to a direct
interaction of endogenous or exogenous IGF-I with hemo-
poietic cells or is it due to enhanced Epo production? To
clearly distinguish between these two possibilities we would
have had to "neutralize" endogenous Epo during GH or
rhIGF-I treatment. However, monospecific antibodies
against rat Epo are not yet available in sufficient amounts to
perform this type of in vivo experiment. Therefore, we used
another approach-we raised serum Epo levels in hypophy-
sectomized rats not receiving GH or IGF-I by repeated
injections of Epo-enriched rat serum and measured 59Fe
incorporation into RBCs as a function of the serum Epo
levels. It turned out that the correlation between these two
indices was strikingly different in the absence from that in the
presence of GH or IGF-I (Fig. 4). Epo appeared to be much
more effective on 59Fe incorporation in the absence than in
the presence of GH or IGF-I, including normal animals, in
which GH and IGF-I are physiologically present. Thus, GH
or IGF-I decreases the sensitivity of erythropoiesis toward
Epo, which may indicate some direct interaction between
IGF-I and erythroid precursor cells in vivo.
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FIG. 4. Correlations between serum Epo concentrations and 59Fe incorporation into RBCs in hypophysectomized rats injected with saline
or Epo-enriched rat serum (o), human GH (28 mu/day) (A), or rhIGF-I (120 .ug/day) (-). Open symbols, IGF-I deprived; closed symbols, IGF-I
repleted group. The linear regression curves y = -18.8 + 2.4x; r = 0.75 (dashed line) for Epo- and saline-treated rats and y = 29.0 + 0.4x;
r = 0.57 (solid line) for GH- and IGF-I-treated rats were significantly different (P < 0.02). The open circle with a cross represents the means
+ SEM of five normal (nonhypophysectomized) male Tif RAI rats.
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This latter contention is supported by four further argu-
ments: (i) the stimulation of 59Fe incorporation by GH or
IGF-I was already increased after 2 days of infusion when
serum Epo was still unaltered; (ii) IGF-I receptors have been
demonstrated on erythroid precursor cells (27); (iii) IGF-I has
been shown to act as a mitogen on late erythroid precursors
in vitro (18-20); (iv) removal of the kidneys, which are
considered as the source of GH-stimulated Epo production
(12), decreases but does not prevent the stimulatory effect of
GH on erythropoiesis (11).
Taken together, the results obtained in this study suggest
that IGF-I may be the factor that governs RBC formation and
organ and body growth and would thus account for the
adaptation of RBC mass to whole body mass.
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